Drug
Tebentafusp clinical trials
Also written IMCgp100 and Kimmtrak.
- studies test it
- 17
- open now
- 9
- in phase 3
- 2
- first study started
- 2010
Keep track of what changes. Save the tebentafusp studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
17 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 12
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 9
Immunocore Ltd (7) · University of Oxford (1) · University of Pennsylvania (1) · Sarcoma Alliance for Research through Collaboration (1) · Grupo Español Multidisciplinar de Melanoma (1) · Diwakar Davar (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Thomas Jefferson University (1)
Often tested with
Tested in the same studies.
Pembrolizumab (2) · Brenetafusp (1) · Antibodies, Monoclonal (1) · Bevacizumab (1) · Percutaneous Hepatic Perfusion (1) · Lexucitug (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses tebentafusp is read from its arms, and is right about nine times in ten.
Testing it · 17
- A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell SarcomaRecruitingPhase 2Sarcoma Alliance for Research through CollaborationNCT06942442Written as Tebentafusp
- Neoadjuvant Tebentafusp in Patients With Metastatic Uveal MelanomaRecruitingPhase 2Grupo Español Multidisciplinar de MelanomaNCT07057596Written as Tebentafusp
- Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal MelanomaRecruitingPhase 2Diwakar DavarNCT06070012Written as Tebentafusp
- Adjuvant Tebentafusp in High Risk Ocular MelanomaRecruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT06246149Written as Tebentafusp
- Neoadjuvant Tebentafusp for Uveal MelanomaRecruitingPhase 2Thomas Jefferson UniversityNCT06414590Written as Tebentafusp-Tebn
- Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT07276386Written as Tebentafusp
- Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)RecruitingPhase 3Immunocore LtdNCT05549297Written as Tebentafusp
- Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal MelanomaRecruitingPhase 2University of MiamiNCT06627244Written as Tebentafusp
- DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid TumorsRecruitingPhase 1DynamiCure BiotechnologyNCT05785754Written as Tebentafusp
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaCompletedPhase 2Immunocore LtdNCT03070392Written as IMCgp100
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsActive, not recruitingPhase 1/2Immunocore LtdNCT04262466Written as Brenetafusp and tebentafusp
- Tebentafusp in Molecular Relapsed Disease (MRD) MelanomaActive, not recruitingPhase 2University of OxfordNCT05315258Written as Tebentafusp
- Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaWithdrawnPhase 1/2Immunocore LtdNCT02535078Written as Tebentafusp (IMCgp100)
- A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal MelanomaCompletedPhase 1/2Immunocore LtdNCT02570308Written as IMCgp100
- IMCgp100-401 Rollover StudyTerminatedPhase 2Immunocore LtdNCT02889861Written as IMCgp100
- Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant MelanomaCompletedPhase 1Immunocore LtdNCT01211262Written as IMCgp100
- IMCgp100 in Advanced Unresectable MelanomaCompletedEarly Phase 1University of PennsylvaniaNCT01209676Written as IMCgp100 injection
Given in every arm · 1 — tebentafusp is usual care beside what is tested
Codes
What other systems call tebentafusp · ClinicalTrials.gg INT001727
- MeSH (NLM) C000719808tebentafuspConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) N658GY6L3ETEBENTAFUSPConfirmed FDA, NLM, Wikidata
- RxNorm 2590743One source FDA
- Wikidata Q110757700tebentafuspConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C94208TebentafuspOne source FDA
- DrugBank DB15283One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719808 | tebentafusp | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | N658GY6L3E | TEBENTAFUSP | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2590743 | — | One source FDA |
| Wikidata | Q110757700 | tebentafusp | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C94208 | Tebentafusp | One source FDA |
| DrugBank | DB15283 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.